IRIS Registry analysis reveals anti-VEGF monotherapies are similarly effective in improving vision

The authors compared real-world visual acuity in neovascular AMD patients who were treated with a single anti–VEGF drug for 1 year.

https://www.aao.org/editors-choice/iris-registry-analysis-reveals-anti-vegf-monothera

Comments

Popular posts from this blog

AGTC Announces Topline Interim Six-Month Data of XLRS Gene Therapy from Ongoing Phase 1/2 Clinical Trial

What to Know About Resveratrol

The Hidden Perils of Eye Rubbing